![ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] logo](/assets/img//header/altuviiio_logo@2x.png "ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] logo"){kind=logo}
![ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] logo](/assets/img//header/logo_mobile@2x.png "ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] logo"){kind=logo}
and scenario
CONNECT WITH A CoRe MANAGER TODAY!
Sanofi Hemophilia Community
Relations and Education (CoRe)
Managers provide information about ALTUVIIIO, living with
hemophilia,
and treatment options.
HIGHER FACTOR
LEVELS FOR LONGER
Above 40% for most of
the week (near-normal
to normal range).*†
HOUR HALF-LIFE
IN ADULTS
In a Phase 3 study,† ALTUVIIIO offered adults
the longest half-life of
any Factor VIII therapy.
BLEEDS
PER YEAR‡
Mean annual bleed rate observed in 128 people previously treated with prophylaxis therapy.†
FREEDOM AND
FLEXIBILITY OF A
ONCE-WEEKLY INFUSION
ALTUVIIIO can also be
used for on-demand and
perioperative use.
*Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 10% for children aged 6 years to under 12 years, and 7% for children aged 1 year to under 6 years.
†159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.
‡Data based on treated bleeds.
HIGHER FACTOR LEVELS FOR LONGER
Above 40% for most of the week (near-normal to normal range).*†
HOUR HALF-LIFE
IN ADULTS
In a Phase 3 study,†
ALTUVIIIO offered adults
the longest half-life of
any Factor VIII therapy.
BLEEDS
PER YEAR‡
Mean annual bleed rate observed in 128 people previously treated with prophylaxis therapy.†
FREEDOM AND FLEXIBILITY OF A ONCE-WEEKLY INFUSION
ALTUVIIIO can also be
used for on-demand
and perioperative use.
*Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 10% for children aged 6 years to under 12 years, and 7% for children aged 1 year to under 6 years.
†159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.
‡Data based on treated bleeds.
Connect With a CoRe Manager
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.
Get Informed. Stay Informed.
Let’s stay in touch. We’ll occasionally send you important information on hemophilia A and ALTUVIIIO.
INDICATION
INDICATION
ALTUVIIIO™ [antihemophilic factor
(recombinant), Fc-VWF-XTEN fusion protein-
ehtl] is an injectable medicine that is used to
control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).
IMPORTANT SAFETY INFORMATION
What is the most important information I need to know about ALTUVIIIO?
Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider’s instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.
INDICATION
INDICATION
ALTUVIIIO™ [antihemophilic factor
(recombinant), Fc-VWF-XTEN fusion protein-
ehtl] is an injectable medicine that is used to
control and reduce the number of bleeding
episodes in people with hemophilia A
(congenital Factor VIII deficiency).
Your healthcare provider may give you
ALTUVIIIO when you have surgery.
IMPORTANT SAFETY INFORMATION
What is the most important information I need to know about ALTUVIIIO?
Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider’s instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.
Who should not use ALTUVIIIO?
You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.
What should I tell my healthcare provider before using ALTUVIIIO?
Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.
What are the possible side effects of ALTUVIIIO?
You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called “inhibitors” against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.
The common side effects of ALTUVIIIO are headache, joint pain, and back pain.
These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.
Please see full Prescribing Information.
Learn more about Sanofi’s commitment to fighting counterfeit drugs.